AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04835571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of cardiovascular risk management
Description: Treatment goals were set according to current guidelines (Perk et al. Eur Guidelines on CVD prevention in clinical practice (2012). Eur heart J. 2012;33(13):1635-701):~* blood pressure \<140/90 mmHg~* Tot cholesterol \<5 mmol/l~* LDL \<1,8 mmol/l~* Waist circumference: men \<94 cm, women \<80 cm~* BMI \<25 kg/m2~* HbA1c without diabetes mellitus \<42 mmol/mol, HbA1c with diabetes mellitus \<52 mmol/mol~* Antithrombotic treatment (or anticoagulants, if indicated)~* Physical activity 30 min/day, 5 days/week, alternatively high-intensity training at least15 min/day, 5 days/week or a combination of the two.~* Healthy diet, including low levels of saturated fats, high intake of vegetables, fruits, whole-grain and fish~* Smoking cessation~* Low alcohol consumption~Patients were encouraged to follow the above recommendations through support of the study physicians, who made individual assessments of all patients and adjusted ongoing medical treatment to reach treatment targets.
Study NCT01324427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual medical visit
Description: At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits.
Study NCT02178800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 Tablets
Description: 30-mg tablets, taken orally
Study NCT02347280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loop Ileostomy with colonic lavage
Description: creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
Study NCT02178800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injectable GSK1265744
Description: Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection
Study NCT02178800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for GSK1265744 Tablets
Description: Taken orally
Study NCT02178800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Placebo for GSK1265744
Description: Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection
Study NCT02347280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Abdominal Colectomy with end ileostomy
Description: Removal of entire colon with preservation of rectal stump and construction of end ileostomy
Study NCT01091168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine
Description: 280 mg/m2 on day 1 of each cycle every 3 weeks
Study NCT01490255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: os, 750 mg, twice per day, for 15 days
Study NCT01490255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: os, 10 mg, once daily, 15 days
Study NCT01091168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alkylating agent of physician choice registered in cancer
Description: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
Study NCT03333018 — intervention group
Intervention type: DRUG
Intervention: Aclidinium bromide
Description: Administered as monotherapy, prescribed as recorded in the database.
Study NCT03333018 — intervention group
Intervention type: DRUG
Intervention: Aclidinium bromide/formoterol
Description: Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
Study NCT03333018 — intervention group
Intervention type: DRUG
Intervention: Other COPD medication
Description: Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database.
Study NCT02261649 — intervention group
Intervention type: DEVICE
Intervention: Medoc Advanced Medical Systems PATHWAY Model ATS
Description: 30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
Study NCT02261649 — intervention group
Intervention type: PROCEDURE
Intervention: Cold water bath
Description: The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
Study NCT02261649 — intervention group
Intervention type: DEVICE
Intervention: MRI scanner
Description: An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
Study NCT04907422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
Description: new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
Study NCT03338400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
Study NCT03338400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
Study NCT03345511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Caudal Block
Description: Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
Study NCT03972618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Installation of water filtration system for filtering existing water source
Description: Installation of water filtration system and education on hand washing.
Study NCT04310696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buteyko Breathing exercises
Description: Buteyko breathing technique was performed by asking the patient to take a small breath in and then out and hold his/her breath and count the time in seconds, as long as he or she can, until first signs of air hunger start to appear, followed by normal breathing once again. This procedure was repeated 15 times, three sets of 15 repetitions were given to the patient per day, 3 days per week and the treatment was continued for 4 weeks.
Study NCT04310696 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pursed lip breathing
Description: Pursed lip breathing was performed as nasal inspiration followed by expiratory blowing against partially closed lips. Participants received a total of 3 sets of 15 repetitions per day, 3 times a week and the treatment was continued for 4 weeks.
Study NCT02681653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
Study NCT02681653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equally matched placebo for 7 days to patients of septic shock admitted to ICU
Study NCT00752492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isocapnic Hyperpnoea
Description: IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
Study NCT05001971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Penpulimab
Description: Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. Penpulimab: 200mg by intravenous drip on day 1 of a 21-day cycle.
Study NCT01803971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy
Description: Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
Study NCT02078752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647263
Description: Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
Study NCT02078752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06647263
Description: Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
Study NCT05524077 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Catheter ablation (CA) will be performed in the standard fashion (described in international guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death from the AHA/ACC/HRS and the expert consensus statement on Catheter Ablation of Ventricular Arrhythmias from HRS/EHRA/APHRS/LAHRS). CA will be performed under conscious sedation or GA by an Electrophysiologist trained in cardiac arrhythmia ablation. CA will be guided by a combination of mapping techniques (standard practice), and described in guidelines for CA for VT. Mapping techniques will include pace, entrainment, activation, and electro-anatomic substrate mapping, where haemodynamically tolerated. Expected procedure duration is 3-6hrs.~Post-CA, AAD is stopped if patient was drug naïve pre-randomisation. The baseline type/dose of AAD pre-randomisation is continued if the patient was on an AAD pre-randomisation. Repeat ablations are permitted within 30-days post-randomisation.
Study NCT05524077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-arrhythmic Drugs (AADs)
Description: Standard care usually encompasses patients who have not previously had AADs, being commenced on sotalol 80mg twice/day. Lower doses may be initiated by treating doctor, as clinically indicated. If there is contraindication to sotalol, another beta-blocker may be initiated using standard doses. Clinicians may consider alternative AADs if there is contraindication to beta-blockers. Doses would be up titrated to the maximal tolerated amount.~For patients already on an AAD, amiodarone would usually be added, as per VANISH trial.~They will receive a loading dose 400mg twice/day for 2 weeks, followed by 400mg/day for 4 weeks and 200mg/day thereafter. Patients who have failed amiodarone dose \<300mg/day will receive a repeat loading dose of 400mg twice/day for 2 weeks, followed by 400mg/day for 1 week, and 300mg/day thereafter.~If the treating doctor decides to do a CA for VT, the occurrence and timepoint of cross-over will be recorded. Cross-over is estimated to be \<2% (VANISH trial).
Study NCT01563900 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto-titration CPAP
Description: An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
Study NCT01563900 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-CPAP
Description: The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
Study NCT03569033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 45 mg will be administered orally.
Study NCT03569033 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching gefapixant will be administered orally.
Study NCT02261649 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
Study NCT01893970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWIFT
Description: Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
Study NCT01893970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SWIFT-Acute
Description: acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
Study NCT01260870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cotavance Paclitaxel Coated Balloon
Study NCT01260870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard balloon angioplasty
Study NCT01388777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visica 2™ Treatment System
Description: The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
Study NCT01388777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
Study NCT01388777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Complete surgical resection of the primary tumor following cryoablation therapy.
Study NCT03859869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Pancrelipase is administered orally as capsules with a meal or snack
Study NCT03859869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally as capsules with a meal or snack
Study NCT03448510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
Study NCT03448510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medication
Description: The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
Study NCT03640949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Arginine
Description: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)
Study NCT03640949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 40 mg methylprednisolone once
Study NCT03640949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: Placebo
Study NCT03608202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POCUS protocol group
Description: The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h.
Study NCT03608202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Routine protocol of the treating team is followed
Study NCT02740283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: glycemic monitoring
Study NCT02740283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary guide
Study NCT00761553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplements with exercise
Description: Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
Study NCT00761553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement without exercise
Description: Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
Study NCT04907422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
Description: conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Study NCT04443296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCRT+TIL
Description: Cisplatin based chemotherapy concurrently with radiotherapy, then TIL infusing following concurrent chemoradiotherapy
Study NCT01135017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)
Study NCT01135017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dronedarone)
Description: Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study NCT00149383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Study NCT00149383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02268071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
Description: For patients with average of HBPM values \<135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
Study NCT04394143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD128
Description: Oral administration of two capsules before sleep for 7 days.
Study NCT04394143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Oral administration of two capsules before sleep for 7 days.
Study NCT03124901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCI pulse oximeter sensor
Study NCT02585076 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: As prescribed by treated physician
Study NCT05565014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virus Activated Killer immune Cells
Description: The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.
Study NCT05565014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The use of saline was the same as VAK group.
Study NCT00688545 — intervention group
Intervention type: DRUG
Intervention: Celecoxib
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Study NCT00688545 — intervention group
Intervention type: DRUG
Intervention: nsNSAIDs
Description: Non-interventional: Treatment assignment as per treating physician's judgement
Study NCT02740218 — intervention group
Intervention type: OTHER
Intervention: Patient questionnaire
Description: Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
Study NCT03527771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-assisted CPR
Description: Emergency call using a Software capable of video Transmission for Video assistance in CPR
Study NCT03527771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telephone-assisted CPR
Description: Emergency call with telephone assistance in CPR
Study NCT03351010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness training program
Description: The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
Study NCT03351010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancer pain educational program
Description: A cancer pain education program by using Videos and personalized face-to-face techniques
Study NCT03351010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer pain educational program
Description: A cancer pain education program by using Videos and personalized face-to-face techniques
Study NCT01457924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 3mg
Description: 3mg of investigational product